The combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) is approved to treat Braf V600E mutant melanoma patients (Robert et al., 2015; Long et al., 2017; Hauschild et al., 2018). Here, MAP2K7 is linked to melanoma.